Evidence map›Paper›PMID 41479055›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Phenotypic Drug Screening for Novel Antifibrotic Therapeutics in Lung Health.

Xin Wei, Arun Kumar Verma, Kevin Merchant, Diana Porras-Gonzalez, Joshua Jäger, Melanie Wögrath, Lin Shen, Ali Önder Yildirim, Michael Gerckens, Gerald Burgstaller

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin WeiInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Arun Kumar VermaInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Kevin MerchantInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Diana Porras-GonzalezInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Joshua JägerInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Melanie WögrathInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Lin ShenInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Ali Önder YildirimInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany.
Michael GerckensInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany. michael.gerckens@helmholtz-munich.de.
Gerald BurgstallerInstitute of Lung Health and Immunity (LHI), Comprehensive Pneumology Center (CPC) with the CPC-M bioArchive, Helmholtz Munich, Member of the German Center for Lung Research (DZL), Munich, Germany. gerald.burgstaller@helmholtz-munich.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung diseases are among the leading causes of death worldwide. Still, noncommunicable pulmonary diseases, such as chronic obstructive pulmonary disease (COPD), and interstitial lung disease (ILD), are lacking curative pharmacotherapies. Either degradation or excessive production of altered pulmonary extracellular matrix (ECM) is a common key feature of those devastating diseases, respectively. Recapitulating those pathological changes in miniaturized cell culture models is key for phenotypic drug discovery approaches targeting the ECM for novel pharmacotherapies in pulmonary disease. We describe here a phenotypic immunofluorescence-based high-content/high-throughput assay in 384-well plate format to measure ECM deposition activity by primary human lung fibroblasts (phLFs) in a pulmonary fibrosis disease context.

Indexed as

Antifibrotic AgentsHigh-Throughput Screening AssaysLungPulmonary FibrosisCells, CulturedDrug DiscoveryDrug Evaluation, PreclinicalExtracellular MatrixFibroblastsHumansPhenotypeAntifibrotic AgentsECM depositionFibroblastHigh-throughput screeningLung fibrosisPhenotypic drug screening

Identifiers

PMID41479055

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.